3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Klatskin Tumor
2
Cholangiocarcinoma
2
Sarcoma, Kaposi
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
Doxorubicin
5
tecogalan
4
Liposomes
4
Vincristine
3
Bleomycin
3
Mitoxantrone
2
ziconotide
1
vesnarinone
1
tin etiopurpurin
1
human papillomavirus vaccine, L1 type 16, 18
1
Zidovudine
1
Tumor Necrosis Factor-alpha
1
Sugars
1
Semaxinib
1
Ro 24-7429
1
Ritonavir
1
Paclitaxel
1
Mitoguazone
1
Maraviroc
1
Maltose
1
Interferon-alpha
1
Inosine Pranobex
1
Etoposide
1
Daunorubicin
1
Cidofovir
1
Bexarotene
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Acquired Immunodeficiency Syndrome
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn